Chemodex

Docetaxel

As low as CHF 41.00

In stock

Only %1 left

CDX-D0371-M0055 mgCHF 41.00

CDX-D0371-M02525 mgCHF 122.00

More Information
Product Details
Synonyms	Taxotere®; NSC 628503; RP 56976; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
Product Type	Chemical
Properties
Formula	C₄₃H₅₃NO₁₄
MW	807.88
CAS	114977-28-5
Source/Host Chemicals	Synthetic.
Purity Chemicals	≥97% (HPLC)
Appearance	White to off-white powder.
Solubility	Soluble in DMSO or ethanol.
Identity	Determined by ¹H-NMR.
Declaration	Manufactured by Chemodex.
Other Product Data	Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key	ZDZOTLJHXYCWBA-VCVYQWHSSA-N
Smiles	CC(C)(OC(N[C@H]([C@H](C(O[C@H]1C[C@@]([C@H]([C@@H]([C@@]2(C([C@@H](C3=C1C)O)=O)C)[C@]4([C@@H](C[C@@H]2O)OC4)OC(C)=O)OC(C5=CC=CC=C5)=O)(C3(C)C)O)=O)O)C6=CC=CC=C6)=O)C
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Protect from light and moisture.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Anticancer agent. Semisynthetic analog of taxol (paclitaxel). Inhibits microtubule disassembly and inhibits cell replication. Binds to and stabilizes the β−tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest at G2/M and apoptosis. This cytotoxic activity has been widely exploited in suppressing oncogenic proliferation. Displays potent and broad antineoplastic properties, used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Also studied for use as a radiation-sensitizing agent.

Product References

(1) M.C. Bissery, et al.; Cancer Res. 51, 4845 (1991) | (2) R. Bruno & G.J. Sanderink; Cancer Surv. 17, 305 (1993) (Review) | (3) K. Gelmon; Lancet 344, 1267 (1994) (Review) | (4) M.E. Trudeau; Can. J. Oncol. 6, 443 (1996) (Review) | (5) I.A. Avramis, et al.; Anticancer Res. 21, 2281 (2001) | (6) M. Aapro & E. Rowinsky; Anticancer Drugs 12, S1 (2001) (Review) | (7) P.B. Cassidy, et al.; Clin. Cancer Res. 8, 846 (2002) | (8) M.S. Si, et al.; Invest. New Drugs 21, 281 (2003) | (9) B. Ramaswamy & S. Puhalla; Drugs Today 42, 265 (2006) (Review) | (10) H. Hernandez-Vargas, et al.; Cell Cycle 6, 780 (2007) (Review) | (11) H. Ching-Hsia, et al.; Toxicol. Sci. 145, 59 (2015)

Call	+41 61 926 6040
Fax	+41 61 926 6049